Research programme: cancer therapeutics - Hanmi Pharmaceuticals

Drug Profile

Research programme: cancer therapeutics - Hanmi Pharmaceuticals

Alternative Names: BTK/JAK dual inhibitor - Hanmi; EGFR mutant selective inhibitors - Hanmi; IAP inhibitor - Hanmi; Inhibitors of apoptosis protein inhibitors - Hanmi

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hanmi Pharmaceutical
  • Class
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Epidermal growth factor receptor antagonists; Inhibitor of apoptosis protein inhibitors; Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for research development in Cancer in South Korea
  • 29 Jun 2011 Early research is ongoing in South Korea
  • 09 Aug 2010 Early research in Cancer in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top